Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.
An article by EHR Intelligence referenced a study published in the January 2020 health information technology issue of The American Journal of Managed Care® (AJMC®). The study, titled “Opt-In Consent Policies: Potential Barriers to Hospital Health Information Exchange,” found that opt-in patient consent requirements for health information exchange correlate with more reported regulatory barriers, especially among less technologically advanced hospitals. The study was additionally spotlighted by Becker’s Hospital Review.
Health IT Analytics’ piece “Machine Learning Uses Social Determinants Data to Predict Utilization” cited a study published in the January 2020 health information technology issue of AJMC® titled, “Using Applied Machine Learning to Predict Healthcare Utilization Based on Socioeconomic Determinants of Care.” The study demonstrated the possibility of generating a highly accurate model to predict inpatient and emergency department utilization through the use of data on socioeconomic determinants of care.
The Kansas City Star featured a May 2018 article on AJMC® titled, “Study Finds Prescription Drug Monitoring Programs Ineffective at Curbing Overdoses.” In the study highlighted in the article, researchers found that prescription drug monitoring programs exhibited limited to no evidence of effectiveness in attacking the nation’s drug problem.
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen